USFDA grants Fast Track Designation to Zydus Usnoflast for amyotrophic lateral sclerosis Ruchika Sharma28 May 2025 9:48 AMUsnoflast (ZYIL1) is a novel, oral small molecule NLRP3 inhibitor.
Zydus Usnoflast gets USFDA Orphan Drug Designation for amyotrophic lateral sclerosis Ruchika Sharma23 Jan 2025 7:45 AMAhmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration (USFDA) has granted...
Zydus Lifesciences gets USFDA nod to conduct Phase II(b) clinical trial for Usnoflast for Amyotrophic Lateral Sclerosis Ruchika Sharma19 Jan 2025 9:15 AMAhmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to conduct Phase...
Zydus Lifesciences completes Phase II(a) clinical trial of Usnoflast in patients with Amyotrophic Lateral Sclerosis Ruchika Sharma11 Sept 2024 7:00 AMAhmedabad: Zydus, a discovery-based, global pharmaceutical company, announced the completion of its Phase II(a) clinical study of NLRP3...
Zydus Lifesciences gets WHO INN approval for 'Usnoflast' as recommended name for ZYIL1 Ruchika Sharma2 April 2024 8:00 AMUsnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus.
